Skip to main content
Publications

Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests JH received speakers fee or honoraria from Janssen-Cilag. JK received honoraria and support for attending meetings from Johnson & Johnson. DS received grants or contracts from Johnson & Johnson and consulting fees from Janssen-Cilag. AK received consulting fees from Janssen Pharmaceutica. UK received travel support, honoraria for advisory boards and invited lectures from Johnson & Johnson/Janssen Germany. GK received honoraria for advisory boards and invited lectures from Johnson & Johnson. TA received a study grant from Johnson & Johnson. ES, RB, MD, CF, SF, MP, FD, TWR, AF, AW, AB, EW, ACP, AK, and GRB declared no conflict of interest in relation to this manuscript.

Discover more